SESSION TITLE: Disorders of the Pleura
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Malignant pleural effusion (MPE) is a common cause of quality of life deterioration in patients with advanced cancer. Management options include chemical pleurodesis with a sclerosing agent such as doxycycline or talc and also the placement of tunneled indwelling pleural catheters (TIPCs). Catheters can be used for outpatient management of MPE, reducing hospital length of stay (LOS) may result in spontaneous pleurodesis. The PleurX (Becton, Dickinson and Company, Franklin Lakes, NJ) TIPC was approved in 1997 by the Food and Drug Administration (FDA) for this purpose and uses plastic vacuum bottles for the drainage; this catheter was used in most studies comparing TIPC vs. other modalities for MPE. Another FDA-approved TIPC system is the Aspira (Bard Access Systems, Salt Lake City, UT), which employs a manually operated vacuum pump for drainage. We conducted a single-center retrospective study with the objective to compare the efficacy and safety of these two different types of catheters.